Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, announced that Erasmus Medical Center in Rotterdam has successfully performed its first procedures using the Genesis Robotic Magnetic Navigation System. Erasmus MC, having completed over 4,500 procedures with Stereotaxis technology, becomes the first center in The Netherlands to implement this advanced system.
The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through cardiac ablation. Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, highlighted the system's enhanced speed and responsiveness, particularly when combined with the MAGiC Catheter, benefiting patients with complex arrhythmias, including children and those with congenital heart disease.
Stereotaxis (NYSE: STXS) has achieved a significant milestone with the completion of the world's first procedures using MAGiC Sweep™, their pioneering robotically-navigated high-density electrophysiology mapping catheter. The procedures were successfully performed at Deborah Heart and Lung Center in New Jersey.
The MAGiC Sweep catheter demonstrated key advantages including accurate mapping of complex anatomy, stable cardiac tissue contact, clear electrogram signals, and absence of ventricular ectopy. Following recent FDA clearance, Stereotaxis has begun the commercial launch in the United States, while European regulatory clearance is pending.
This breakthrough represents a major advancement in robotic electrophysiology, with the technology already used to treat over 150,000 patients globally across the United States, Europe, and Asia.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences in New York City this September. CEO David Fischel will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th, 2025, at 8:00 am EDT, and attend the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th, 2025.
The company, which has treated over 150,000 patients globally with its robotic technology, will discuss its technological and commercial progress in its growth strategy. One-on-one meetings with Mr. Fischel can be arranged through conference registration.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will showcase its technology at the upcoming HRX digital health conference from September 4-6, 2025, in Atlanta.
CEO David Fischel will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Following this, at 4:45 PM EDT, a panel of electrophysiologists will lead a session titled "Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes", exploring robotics, AR/VR, AI, and automation in cardiac care.
The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, reported its Q2 2025 financial results with significant growth. Total revenue reached $8.8 million, up 95% year-over-year and 18% sequentially. System revenue was $3.0 million, while recurring revenue grew 35% to $5.8 million.
The company achieved a notable milestone with FDA clearance of MAGiC Sweep, its first interventional catheter approval in nearly 20 years. Gross margin was 52%, with recurring revenue margin at 68% and system margin at 22%. The quarter ended with $7.0 million in cash, subsequently strengthened by a $12.5 million strategic financing in July.
Management reiterated expectations of double-digit revenue growth for 2025, projecting $2-3 million quarterly system revenue and recurring revenue scaling to $7 million by Q4 2025.
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, has received FDA 510(k) clearance for its MAGiC Sweep™ catheter, the world's first robotically navigated high-density electrophysiology mapping catheter. The innovative device features 20 electrodes for detailed cardiac mapping and integrates with Stereotaxis' Robotic Systems.
The MAGiC Sweep catheter offers significant advantages including efficient high-density mapping, extended reach and precision, atraumatic design, and improved anatomical accuracy. This marks Stereotaxis' first FDA clearance for an interventional catheter in nearly 20 years and represents a crucial milestone in the company's comprehensive innovation strategy for advancing robotics in electrophysiology.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will release its Q2 2025 financial results on August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. The company specializes in developing robotic systems, instruments, and information solutions for interventional laboratories, focusing on enhancing physician care delivery with robotic precision and safety.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced a $12.5 million registered direct offering of common stock at $2.00 per share. The offering is led by a strategic industry partner and select institutional investors.
The financing will be completed in two closings: an initial $8.5 million closing around July 18, 2025, and a second $4.0 million closing by November 25, 2025. Lake Street Capital Markets LLC serves as the exclusive placement agent. The proceeds will support product commercialization, research and development, and other corporate purposes.
Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, announced the publication of first clinical results for its MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The prospective multi-center study demonstrated an impressive 94% acute efficacy rate in treating various heart arrhythmias.
The study, conducted at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos, included 67 patients with various arrhythmias. The average procedure time was 83 minutes skin-to-skin, with a low procedure-related adverse event rate of 1.5%. Patient enrollment continues with approximately 100 patients enrolled to date, with efficacy assessments ongoing for up to one year.
The MAGiC catheter, designed for robotically-navigated magnetic ablation procedures, showed notable improvements in stability, eliminating the need for sheaths for catheter support. The technology has already been utilized in treating over 150,000 patients across leading hospitals globally.